Cargando…

Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml

BACKGROUND: This study aimed to analyze the pathological characteristics and predictive factors of prostate biopsy in men with PSA levels below 4.0 ng/ml. PATIENTS AND METHODS: We retrospectively analyzed 158 patients who underwent prostate biopsy with PSA levels below 4.0 ng/ml. Pathological result...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Rui, Pan, Jin-feng, Ren, Da-wei, Jiang, Jun-hui, Ma, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365965/
https://www.ncbi.nlm.nih.gov/pubmed/35965573
http://dx.doi.org/10.3389/fonc.2022.957892
_version_ 1784765450916200448
author Su, Rui
Pan, Jin-feng
Ren, Da-wei
Jiang, Jun-hui
Ma, Qi
author_facet Su, Rui
Pan, Jin-feng
Ren, Da-wei
Jiang, Jun-hui
Ma, Qi
author_sort Su, Rui
collection PubMed
description BACKGROUND: This study aimed to analyze the pathological characteristics and predictive factors of prostate biopsy in men with PSA levels below 4.0 ng/ml. PATIENTS AND METHODS: We retrospectively analyzed 158 patients who underwent prostate biopsy with PSA levels below 4.0 ng/ml. Pathological results were statistically analyzed. The logistic regression analysis was used to determine the predictive factors for malignant outcomes. Subgroup analysis was performed on patients who received surgery and the postoperative pathological upgrading was counted. RESULTS: A total of 143 patients were enrolled. The tumor detection rate was 20.3%. Among these patients, most of them (79.3%) had prostate adenocarcinoma, but rare malignant tumors also accounted for 20.7%. Logistic regression analysis indicated that the only independent predictive factor for a positive prostate biopsy was the PI-RADS score. For prostate adenocarcinoma cases, 95.7% of them were organ localized and 47.8% of cases were clinically significant. Subgroup analysis was performed on 14 patients who received surgical treatment. 28.6% of patients were upgraded to clinically significant prostate cancer, while 64.3% of patients had an upgrade in tumor stage. CONCLUSION: Our study indicated that 20.3% of men with PSA levels between 0 and 4.0 ng/ml were diagnosed with prostate malignancies. Among these patients, most of them (79.3%) were diagnosed with prostate adenocarcinoma, and several uncommon types of malignancies were also detected in 20.7% of patients. The only risk factor for a positive biopsy in patients with a low PSA concentration was the PI-RADS score. It should be emphasized that the invasiveness of PCa patients diagnosed by biopsy may be underestimated as more than half of patients will upgrade their Gleason score or clinical stages after surgery. Thus, clinicians should pay more attention to patients with PSA levels between 0 and 4.0 ng/ml.
format Online
Article
Text
id pubmed-9365965
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93659652022-08-12 Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml Su, Rui Pan, Jin-feng Ren, Da-wei Jiang, Jun-hui Ma, Qi Front Oncol Oncology BACKGROUND: This study aimed to analyze the pathological characteristics and predictive factors of prostate biopsy in men with PSA levels below 4.0 ng/ml. PATIENTS AND METHODS: We retrospectively analyzed 158 patients who underwent prostate biopsy with PSA levels below 4.0 ng/ml. Pathological results were statistically analyzed. The logistic regression analysis was used to determine the predictive factors for malignant outcomes. Subgroup analysis was performed on patients who received surgery and the postoperative pathological upgrading was counted. RESULTS: A total of 143 patients were enrolled. The tumor detection rate was 20.3%. Among these patients, most of them (79.3%) had prostate adenocarcinoma, but rare malignant tumors also accounted for 20.7%. Logistic regression analysis indicated that the only independent predictive factor for a positive prostate biopsy was the PI-RADS score. For prostate adenocarcinoma cases, 95.7% of them were organ localized and 47.8% of cases were clinically significant. Subgroup analysis was performed on 14 patients who received surgical treatment. 28.6% of patients were upgraded to clinically significant prostate cancer, while 64.3% of patients had an upgrade in tumor stage. CONCLUSION: Our study indicated that 20.3% of men with PSA levels between 0 and 4.0 ng/ml were diagnosed with prostate malignancies. Among these patients, most of them (79.3%) were diagnosed with prostate adenocarcinoma, and several uncommon types of malignancies were also detected in 20.7% of patients. The only risk factor for a positive biopsy in patients with a low PSA concentration was the PI-RADS score. It should be emphasized that the invasiveness of PCa patients diagnosed by biopsy may be underestimated as more than half of patients will upgrade their Gleason score or clinical stages after surgery. Thus, clinicians should pay more attention to patients with PSA levels between 0 and 4.0 ng/ml. Frontiers Media S.A. 2022-07-28 /pmc/articles/PMC9365965/ /pubmed/35965573 http://dx.doi.org/10.3389/fonc.2022.957892 Text en Copyright © 2022 Su, Pan, Ren, Jiang and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Su, Rui
Pan, Jin-feng
Ren, Da-wei
Jiang, Jun-hui
Ma, Qi
Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
title Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
title_full Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
title_fullStr Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
title_full_unstemmed Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
title_short Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
title_sort pathological characteristics and predictive factors of prostate biopsy in patients with serum psa levels between 0 and 4.0 ng/ml
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365965/
https://www.ncbi.nlm.nih.gov/pubmed/35965573
http://dx.doi.org/10.3389/fonc.2022.957892
work_keys_str_mv AT surui pathologicalcharacteristicsandpredictivefactorsofprostatebiopsyinpatientswithserumpsalevelsbetween0and40ngml
AT panjinfeng pathologicalcharacteristicsandpredictivefactorsofprostatebiopsyinpatientswithserumpsalevelsbetween0and40ngml
AT rendawei pathologicalcharacteristicsandpredictivefactorsofprostatebiopsyinpatientswithserumpsalevelsbetween0and40ngml
AT jiangjunhui pathologicalcharacteristicsandpredictivefactorsofprostatebiopsyinpatientswithserumpsalevelsbetween0and40ngml
AT maqi pathologicalcharacteristicsandpredictivefactorsofprostatebiopsyinpatientswithserumpsalevelsbetween0and40ngml